A new study supports strict adherence to guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets following ...
Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...
Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and ...
In a large randomized trial involving patients with type 2 diabetes and established atherosclerotic cardiovascular disease, ...
Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...
Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...
Artificial intelligence-enabled point-of-care EEG allows rapid bedside seizure detection, accelerating treatment and preventing unnecessary care escalation.
Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains ...
Coronary artery disease (CAD) remains highly prevalent in the Indian population, with Indians facing a three-four times ...
The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...
The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.
Chronic sleep deprivation acts as a systemic stressor, elevating risks for cardiovascular disease and metabolic dysregulation while impairing cognitive function.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback